Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)

PAR-22-123

The primary objective of this FOA is to support Bioengineering Partnerships with Industry (BPI) to: 1) establish a robust engineering solution to a problem in biomedical research or the practice of medicine; 2) develop a strategic alliance of multi-disciplinary partners, one of which must be an industrial partner, based on a well-defined leadership plan; and 3) realize a specific endpoint and deliverables within 5-10 years based on a detailed plan with a timeline and quantitative milestones.

A distinguishing feature of this FOA will be the requirement of an appropriate academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution to advance human health. These partnerships are expected to solidify pre-existing collaborations or spur the creation of new collaborations to drive the fields of bioengineering and biomedical imaging further than if they had not been formed.

Achieving the goal of the BPI program will likely require leveraging the expertise of engineering and the life, physical, or computational sciences. Engaging clinical researchers or clinician scientists in the relevant biomedical fields, when appropriate, is strongly encouraged, although not required.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

30 days prior to the application due date

May 26, 2022; September 26, 2022

I. George Zubal, Ph.D.; National Institute of Biomedical Imaging and Bioengineering (NIBIB); Telephone:301-827-5168; Email: igeorge.zubal@nih.gov